Stock DNA
Other Agricultural Products
CAD 31 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.25
-25.53%
0.78
Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.14%
0%
-7.14%
6 Months
-13.33%
0%
-13.33%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
-23.53%
0%
-23.53%
4 Years
-66.67%
0%
-66.67%
5 Years
-88.98%
0%
-88.98%
MediPharm Labs Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-15.11%
EBIT Growth (5y)
10.52%
EBIT to Interest (avg)
-20.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.74
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.78
EV to EBIT
-2.44
EV to EBITDA
-3.13
EV to Capital Employed
0.71
EV to Sales
0.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-29.09%
ROE (Latest)
-25.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
11.80
10.80
9.26%
Operating Profit (PBDIT) excl Other Income
-3.60
-0.20
-1,700.00%
Interest
0.00
0.00
Exceptional Items
0.50
0.40
25.00%
Consolidate Net Profit
-3.80
-0.40
-850.00%
Operating Profit Margin (Excl OI)
-336.30%
-62.10%
-27.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.26% vs -10.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -850.00% vs 76.47% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
42.00
33.10
26.89%
Operating Profit (PBDIT) excl Other Income
-9.10
-16.40
44.51%
Interest
0.60
0.40
50.00%
Exceptional Items
1.10
1.60
-31.25%
Consolidate Net Profit
-10.70
-13.10
18.32%
Operating Profit Margin (Excl OI)
-278.90%
-570.70%
29.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 26.89% vs 49.77% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 18.32% vs 56.33% in Dec 2023
About MediPharm Labs Corp. 
MediPharm Labs Corp.
Other Agricultural Products
Medipharm Labs Corp, formerly known as POCML 4 Inc, is a Canada-based medicinal cannabis company specializing in the pharmaceutical grade production of cannabis. The Company is focused on distillation and cannabinoid isolation and purification. The Company actively builds an inventory of specialized consumer products in anticipation of federal legalization of the adult-use market in Canada. Outside of the Canadian market, the Company develops MediPharm Labs Australia facility, which is a purpose-built and component of the Company’s international investments. The Company operates with a processing capacity of approximately 100,000 kilograms of dry cannabis flower and trim per year.
Company Coordinates 
Company Details
151 John St , BARRIE ON : L4N 2L1
Registrar Details






